Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Nirogi R, Shinde A, Goyal VK, Ravula J, Benade V, Jetta S, Pandey SK, Subramanian R, Chowdary Palacharla VR, Mohammed AR, Abraham R, Dogiparti DK, Kalaikadhiban I, Jayarajan P, Jasti V, Bogan RK. Nirogi R, et al. Among authors: jasti v. Sleep Med. 2024 Dec;124:618-626. doi: 10.1016/j.sleep.2024.10.037. Epub 2024 Oct 30. Sleep Med. 2024. PMID: 39504585 Clinical Trial.
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease.
Nirogi R, Shinde A, Kambhampati RS, Mohammed AR, Saraf SK, Badange RK, Bandyala TR, Bhatta V, Bojja K, Reballi V, Subramanian R, Benade V, Palacharla RC, Bhyrapuneni G, Jayarajan P, Goyal V, Jasti V. Nirogi R, et al. Among authors: jasti v. J Med Chem. 2017 Mar 9;60(5):1843-1859. doi: 10.1021/acs.jmedchem.6b01662. Epub 2017 Feb 17. J Med Chem. 2017. PMID: 28212021
Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity.
Nirogi R, Shinde A, Mohammed AR, Badange RK, Reballi V, Bandyala TR, Saraf SK, Bojja K, Manchineella S, Achanta PK, Kandukuri KK, Subramanian R, Benade V, Palacharla RC, Jayarajan P, Pandey S, Jasti V. Nirogi R, et al. Among authors: jasti v. J Med Chem. 2019 Feb 14;62(3):1203-1217. doi: 10.1021/acs.jmedchem.8b01280. Epub 2019 Jan 25. J Med Chem. 2019. PMID: 30629436
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression.
Nirogi R, Mohammed AR, Shinde AK, Ravella SR, Bogaraju N, Subramanian R, Mekala VR, Palacharla RC, Muddana N, Thentu JB, Bhyrapuneni G, Abraham R, Jasti V. Nirogi R, et al. Among authors: jasti v. J Med Chem. 2020 Mar 26;63(6):2833-2853. doi: 10.1021/acs.jmedchem.9b00790. Epub 2020 Feb 21. J Med Chem. 2020. PMID: 32026697
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders.
Nirogi R, Grandhi VR, Medapati RB, Ganuga N, Benade V, Gandipudi S, Manoharan A, Abraham R, Jayarajan P, Bhyrapuneni G, Shinde A, Badange RK, Subramanian R, Petlu S, Jasti V. Nirogi R, et al. Among authors: jasti v. J Psychopharmacol. 2021 Jun;35(6):713-729. doi: 10.1177/0269881120986418. Epub 2021 Feb 5. J Psychopharmacol. 2021. PMID: 33546570
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
Nirogi R, Benade V, Daripelli S, Subramanian R, Kamuju V, Bhyrapuneni G, Muddana NR, Mekala VR, Petlu S, Jayarajan P, Badange R, Shinde A, Jasti V. Nirogi R, et al. Among authors: jasti v. Psychopharmacology (Berl). 2021 Jun;238(6):1495-1511. doi: 10.1007/s00213-021-05779-x. Epub 2021 Feb 7. Psychopharmacology (Berl). 2021. PMID: 33550481
Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease.
Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Ravella SR, Bogaraju N, Middekadi VR, Subramanian R, Palacharla RC, Benade V, Muddana N, Abraham R, Medapati RB, Thentu JB, Mekala VR, Petlu S, Lingavarapu BB, Yarra S, Kagita N, Goyal VK, Pandey SK, Jasti V. Nirogi R, et al. Among authors: jasti v. J Med Chem. 2021 Aug 12;64(15):10641-10665. doi: 10.1021/acs.jmedchem.1c00703. Epub 2021 Jul 12. J Med Chem. 2021. PMID: 34251799
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
Nirogi R, Abraham R, Jayarajan P, Goura V, Kallepalli R, Medapati RB, Tadiparthi J, Goyal VK, Pandey SK, Subramanian R, Petlu S, Thentu JB, Palacharla VRC, Gagginapally SR, Mohammed AR, Jasti V. Nirogi R, et al. Among authors: jasti v. Psychopharmacology (Berl). 2022 Jul;239(7):2215-2232. doi: 10.1007/s00213-022-06108-6. Epub 2022 Mar 17. Psychopharmacology (Berl). 2022. PMID: 35298691
Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.
Nirogi R, Ieni J, Goyal VK, Ravula J, Jetta S, Shinde A, Jayarajan P, Benade V, Palacharla VRC, Dogiparti DK, Jasti V, Atri A, Cummings J. Nirogi R, et al. Among authors: jasti v. Alzheimers Dement (N Y). 2022 Jun 1;8(1):e12307. doi: 10.1002/trc2.12307. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35662833 Free PMC article.
34 results